Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are a novel class of oral diabetes drugs that block the reabsorption of glucose via SGLT2 in the proximal tubules of the kidneys, allowing glucose to be excreted in the urine, and achieve the therapeutic effect of lowering blood sugar1. Here, SLC5A2 is linked to diabetes mellitus.